Halozyme Therapeutics Stock Price Patterns
| HALO Stock | USD 76.92 2.59 3.26% |
Momentum 59
Buy Extended
Oversold | Overbought |
Quarterly Earnings Growth 0.362 | EPS Estimate Next Quarter 0.9562 | EPS Estimate Current Year 6.554 | EPS Estimate Next Year 8.18 | Wall Street Target Price 78 |
Using Halozyme Therapeutics hype-based prediction, you can estimate the value of Halozyme Therapeutics from the perspective of Halozyme Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Halozyme Therapeutics using Halozyme Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Halozyme using crowd psychology based on the activity and movement of Halozyme Therapeutics' stock price.
Halozyme Therapeutics Short Interest
An investor who is long Halozyme Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Halozyme Therapeutics and may potentially protect profits, hedge Halozyme Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 65.265 | Short Percent 0.1601 | Short Ratio 7.55 | Shares Short Prior Month 13.6 M | 50 Day MA 69.933 |
Halozyme Therapeutics Hype to Price Pattern
Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Halozyme Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Halozyme Therapeutics.
Halozyme Therapeutics Implied Volatility | 0.65 |
Halozyme Therapeutics' implied volatility exposes the market's sentiment of Halozyme Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Halozyme Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Halozyme Therapeutics stock will not fluctuate a lot when Halozyme Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Halozyme Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Halozyme because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Halozyme Therapeutics after-hype prediction price | USD 76.63 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Halozyme contract
Based on the Rule 16, the options market is currently suggesting that Halozyme Therapeutics will have an average daily up or down price movement of about 0.0406% per day over the life of the 2026-03-20 option contract. With Halozyme Therapeutics trading at USD 76.92, that is roughly USD 0.0312 . If you think that the market is fully incorporating Halozyme Therapeutics' daily price movement you should consider acquiring Halozyme Therapeutics options at the current volatility level of 0.65%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections. Halozyme Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Halozyme Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Halozyme Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Halozyme Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Halozyme Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Halozyme Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Halozyme Therapeutics' historical news coverage. Halozyme Therapeutics' after-hype downside and upside margins for the prediction period are 74.54 and 78.72, respectively. We have considered Halozyme Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Halozyme Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Halozyme Therapeutics is based on 3 months time horizon.
Halozyme Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Halozyme Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.17 | 2.10 | 0.60 | 0.26 | 5 Events / Month | 5 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
76.92 | 76.63 | 0.38 |
|
Halozyme Therapeutics Hype Timeline
Halozyme Therapeutics is currently traded for 76.92. The entity has historical hype elasticity of 0.6, and average elasticity to hype of competition of -0.26. Halozyme is expected to decline in value after the next headline, with the price expected to drop to 76.63. The average volatility of media hype impact on the company price is about 59.66%. The price decrease on the next news is expected to be -0.38%, whereas the daily expected return is currently at 0.17%. The volatility of related hype on Halozyme Therapeutics is about 137.86%, with the expected price after the next announcement by competition of 76.66. About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003. Given the investment horizon of 90 days the next expected press release will be in about 5 days. Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections.Halozyme Therapeutics Related Hype Analysis
Having access to credible news sources related to Halozyme Therapeutics' direct competition is more important than ever and may enhance your ability to predict Halozyme Therapeutics' future price movements. Getting to know how Halozyme Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Halozyme Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CORT | Corcept Therapeutics Incorporated | 2.48 | 13 per month | 0.00 | (0.09) | 6.44 | (8.51) | 55.08 | |
| ABVX | Abivax SA American | (9.61) | 8 per month | 3.39 | 0.06 | 6.94 | (6.09) | 29.38 | |
| RYTM | Rhythm Pharmaceuticals | 3.74 | 11 per month | 0.00 | (0.03) | 4.76 | (4.28) | 18.69 | |
| CYTK | Cytokinetics | (1.12) | 7 per month | 2.31 | 0.03 | 4.25 | (3.67) | 12.08 | |
| JAZZ | Jazz Pharmaceuticals PLC | (1.93) | 9 per month | 1.55 | 0.10 | 3.66 | (3.14) | 25.96 | |
| CAI | Caris Life Sciences | (3.10) | 10 per month | 0.00 | (0.13) | 3.96 | (4.91) | 17.67 | |
| GRFS | Grifols SA ADR | 0.06 | 3 per month | 1.65 | 0.04 | 3.23 | (3.28) | 8.28 | |
| HSIC | Henry Schein | (0.54) | 7 per month | 1.46 | 0.04 | 2.43 | (2.60) | 6.00 | |
| ATR | AptarGroup | (3.69) | 9 per month | 1.09 | 0.13 | 2.93 | (1.51) | 8.45 |
Halozyme Therapeutics Additional Predictive Modules
Most predictive techniques to examine Halozyme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Halozyme using various technical indicators. When you analyze Halozyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Halozyme Therapeutics Predictive Indicators
The successful prediction of Halozyme Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Halozyme Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Halozyme Therapeutics based on analysis of Halozyme Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Halozyme Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Halozyme Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 16.28 | 15.55 | 14.0 | 14.7 | Days Of Inventory On Hand | 242.12 | 324.8 | 373.52 | 574.15 |
Pair Trading with Halozyme Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Halozyme Stock
| 0.72 | LYRA | Lyra Therapeutics | PairCorr |
| 0.66 | EDIT | Editas Medicine Earnings Call This Week | PairCorr |
| 0.65 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.64 | ABP | Abpro Holdings | PairCorr |
| 0.64 | KURA | Kura Oncology | PairCorr |
| 0.61 | LRMR | Larimar Therapeutics | PairCorr |
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Halozyme diversify its offerings? Factors like these will boost the valuation of Halozyme Therapeutics. Market participants price Halozyme higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Halozyme Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.362 | Earnings Share 4.7 | Revenue Per Share | Quarterly Revenue Growth 0.221 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Halozyme Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.